Gbt

Section 1: Chemical Identification
Chemical name: Tetracycline Hydrochloride
Identity (As used on label and list): Tetracycline Hydrochloride
Gold Biotechnology, Inc.
Section 2: Composition/Information on Ingredients
Section 3: Hazardous Ingredients/Identity Information
Irritant; May be harmful if swallowed, inhaled or absorbed through skin. Photo sensitizerCalifornia Prop. 65 reproductive hazardTarget organ(s): Liver, teeth, bonesHMIS Rating: Section 4: First Aid Measures
If inhaled: remove to fresh air, consult a physicianIn case of skin contact: immediately wash skin with soap and water, consult a physicianIn case of eye contact: rinse out with water, with the eyelid held wide open, flush for 15 minutes, If swallowed: wash out mouth with water, make victim drink plenty of water, induce vomiting, Section 5: Fire Fighting Measures
Flash point: N/A
Extinguishing media: water, carbon dioxide, dry chemical powder or foam
Special fire fighting procedures: wear self-contained breathing apparatus and protective
clothing to prevent contact with skin and eyes Unusual fire and explosion hazards: emits toxic fumes under fire conditions Section 6: Accidental Release Measures
Evacuate and ventilate the areaWear respirator and protective clothingSweep up dry, place in bag and hold for waste disposalVentilate area and wash spill site after material pick-up is completeAvoid generation of dusts Section 7: Storage
Store in tightly closed container, desiccated, at room temperature, away from light Section 8: Control Measures
Respiratory protection: NIOSH/MSHA-approved respirator, do not breathe dustVentilation: mechanical exhaust requiredProtective gloves: chemical-resistant gloves requiredEye protection: safety goggles Work/hygienic practices: avoid contact with eyes, skin and clothing; wash skin thoroughly and remove contaminated clothing after handling Section 9: Physical And Chemical Properties
Solubility: slightly soluble in water, ethanol Section 10: Stability And Reactivity Data
Stability: stable under ordinary conditions of use and storageMaterials to avoid: oxidizing agentsConditions to avoid: moisture, lightHazardous decomposition or byproducts: carbon monoxide, carbon dioxide, nitrogen oxide and hydrogen chloride gas Hazardous polymerization: will not occur Section 11: Toxicological Information
Acute Toxicity
Oral:
LD50 mouse 2759 mg/kg, LD50 rat 6443 mg/kg May cause irritation; may be harmful if absorbed through the skin Possible allergic reaction in certain sensitive individuals Chronic toxicity:
Result: Possible risk of congenital malformation in the fetus Species: RatDose: 14 gm/kgRoute of Application: OralExposure time: (3D Male/3D Pre-22D PREG)Specific developmental abnormalities: Musculoskeletal, urogenital system Species: RatDose: 240 mg/kgRoute of Application: SubcutaneousExposure time: (16-20D PREG)Effects on embryo or fetus: other effects to embryo Species: RatDose: 240 mg/kgRoute of Application: IntramuscularExposure time: (10-15D PREG)Effects on embryo or fetus: fetotoxicity Section 11: Toxicological Information (continued)
Species: MouseDose: 600 mg/kgRoute of Application: IntraperitonealExposure time: (8-13D PREG)Effects on embryo or fetus: fetotoxicity Species: MouseDose: 150 mg/kgRoute of Application: IntraperitonealExposure time: (10D PREG)Specific Abnormalities: Musculoskeletal system Species: MouseDose: 2250 mg/kgRoute of Application: SubcutaneousExposure time: (10-18D PREG)Specific Abnormalities: Urogenital systemEffects: Viability index and growth statistics Chronic Exposure: Mutagen
Mutation test: Other mutation test systems Effects on fertility: Abortion, extra embryonic Section 11: Toxicological Information (continued)
Chronic Exposure: Reproductive Hazard
Effects on embryo: fetal deathEffects on fertility: post-implantation mortality Developmental abnormalities: musculoskeletal Route of application: subcutaneousExposure time: (1-6D PREG) Dose: 2250 mg/kgRoute of application: parenteral Route of application: OralExposure time: (8-16D PREG)Effects on fertility: post-implantation mortality Section 12: Ecological Information
Section 13: Disposal Considerations
Disposal should be handled by an approved waste disposal facility Section 14: Transport Information
DOT/IATA: This material is considered to be non-hazardous for transport Section 15: Regulatory Information
Indication of Danger: IrritantRisk Statements: Irritating to eyes, respiratory system and skinSafety Statements: In case of accident or if you feel unwell, seek medical advice immediately(show the label where possible)Wear suitable protective clothing.
US Statements: Photosensitizer, California Prop 65 reproductive hazard. Target organ(s): Liver, teeth, bones SARA Listed: YDeminimis: 1%Notes: This product is subject to SARA section 313 reporting requirements.
TSCA Inventory Item: Y United States—State Regulatory Infromation This product is or contains chemical(s) known to the state of California to cause developmental toxicity. WHMIS: This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all the information required by the CPR.
DSL: YNDSL: N Section 16: Other Information
While Gold Biotechnology, Inc. believes the information contained herein to be true and accurate, it has relied on information provided by others. Gold Biotechnology, Inc. makes no warranties, express or implied, as to the accuracy or adequacy of the information contained herein or with respect to the results to be obtained from the use of the product. Gold Biotechnology, Inc. disclaims all liability with respect to the use of this product, including without limitation, liability for injury to the user or third-party persons.

Source: http://www.labimport.com/uploads/file_47363712.pdf

Microsoft word - return h+p 100112.docx

HILO OBSTETRICS & GYNECOLOGY – QUYEN TRAN, M.D. Name____________________________________ DOB ________________ Age_____ Date_____________ Reason for this visit:_________________________________________________________________________ Please circle all changes that apply to your health in the last 6 months: □ No changes GENERAL : weight gain or loss (____ lbs), fe

Effective date:

Easy Choice Health Plan Step Therapy Requirements Effective Date: 11/01/2013 STEP THERAPY GROUP DESCRIPTION ANALGESICS, NARCOTICS DRUG NAME KADIAN | MORPHINE SULFATE ER STEP THERAPY CRITERIA PRIOR CLAIM FOR MORPHINE SULFATE SUSTAINED ACTION TABLET (MS CONTIN) WITHIN THE PAST 120 DAYS. Easy Choice Health Plan Step Therapy Requirements Effective Date: 11/0

Copyright © 2010-2014 Metabolize Drugs Pdf